{ "company": "Natera", "ticker": "NTRA", "period": { "from": "2026-03-16", "to": "2026-04-15", "days": 30 }, "sentiment_breakdown": { "positive": 41, "negative": 39, "neutral": 28 }, "synthesis": { "executive_summary": "Sentiment analysis for Natera (NTRA) from 2026-03-16 to 2026-04-15. Analyzed 108 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.812 }, { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.812 }, { "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.753 }, { "title": "Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth?", "date": "2026-04-14", "source": "alpha_vantage", "score": 0.71 }, { "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "date": "2026-03-29", "source": "alpha_vantage", "score": 0.66 }, { "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "date": "2026-03-27", "source": "news", "score": 0.637 }, { "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.586 }, { "title": "William Blair initiates Natera stock with Outperform on growth outlook", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.582 }, { "title": "Angels George Klassen's inspiring journey back from head injury to MLB debut", "date": "2026-04-11", "source": "news", "score": 0.572 }, { "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.572 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "date": "2026-04-15", "source": "pubmed", "score": -0.848 }, { "title": "ATM functions as a rheostat of metabolic stress in small-cell lung cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.802 }, { "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "date": "2026-04-15", "source": "pubmed", "score": -0.791 }, { "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.765 }, { "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "date": "2026 Apr 9", "source": "pubmed", "score": -0.758 }, { "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "date": "2026-04-01", "source": "alpha_vantage", "score": -0.66 }, { "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.66 }, { "title": "Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 108, "items": [ { "source": "news", "source_name": "GlobeNewswire", "title": "American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease", "description": "ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members support AKF in fighting kidney disea…", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272711/0/en/American-Kidney-Fund-Announces-2026-Class-of-Corporate-Members-Supporting-Work-to-Fight-Kidney-Disease.html", "date": "2026-04-13", "published_at": "2026-04-13T15:37:00Z", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "news", "source_name": "USA Today", "title": "Angels George Klassen's inspiring journey back from head injury to MLB debut", "description": "About a year ago, the Angels No. 3 prospect George Klassen was in the hospital. Now, he's getting ready to make his second big league start Saturday.", "url": "https://www.usatoday.com/story/sports/mlb/angels/2026/04/11/george-klassen-los-angeles-angels-mental-hurdles-concussion/89565733007/", "date": "2026-04-11", "published_at": "2026-04-11T14:23:33Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html", "date": "2026-04-07", "published_at": "2026-04-07T16:23:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "description": "Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html", "date": "2026-03-27", "published_at": "2026-03-27T14:44:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider", "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…", "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html", "date": "2026-03-17", "published_at": "2026-03-17T11:45:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-01", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926038519/0001104659-26-038519-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst", "url": "https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51815723/natera-positioned-to-capture-growing-20-billion-mrd-opportunity-analyst", "date": "2026-04-14", "summary": "William Blair initiated coverage on Natera (NASDAQ: NTRA), emphasizing the company's strong position in the growing minimal residual disease (MRD) testing market, estimated at over $20 billion. Analyst Andrew Brackmann projects Natera's MRD revenue, estimated at nearly $1 billion in 2025, to grow over 40% in 2026 and potentially fivefold over time. Natera's competitive advantages in clinical evidence, commercial infrastructure, and a diversified multi-segment strategy, including noninvasive pren", "sentiment_score": 0.47004, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "NTRA Initiated Coverage On by William Blair -- Rating Outperform", "url": "https://www.gurufocus.com/news/8792438/ntra-initiated-coverage-on-by-william-blair-rating-outperform", "date": "2026-04-14", "summary": "William Blair analyst Andrew Brackmann initiated coverage on Natera (NTRA) with an 'Outperform' rating, signaling a positive outlook for the genetic testing company. Despite this, GuruFocus assesses NTRA as approximately 14.1% overvalued, with significant insider selling amounting to $124.1 million in the last three months. The company boasts a high GF Score™ of 85/100, driven by strong growth potential, though its profitability ranks lower.", "sentiment_score": 0.274664, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth?", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/natera-inc-stock-us6323071042-is-cell-free-dna-testing-strong-enough-to/69145512", "date": "2026-04-14", "summary": "Natera Inc. is a leader in cell-free DNA testing, offering diagnostics for cancer monitoring (Signatera) and prenatal screening (Panorama), primarily targeting the U.S. and English-speaking markets. The company leverages proprietary algorithms and R&D to drive accuracy and scalability, positioning itself as a strong player in the high-growth diagnostics sector. Despite risks like reimbursement volatility and intense competition, analysts view the stock positively due to robust test volume growth", "sentiment_score": 0.408626, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.71, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Lymphoma patients on Allogene therapy saw ctDNA drop 97.7% by Day 45", "url": "https://www.stocktitan.net/news/NTRA/natera-highlights-positive-interim-futility-analysis-from-allogene-reiwpxdxw5s5.html", "date": "2026-04-14", "summary": "Natera highlighted interim futility analysis results from Allogene Therapeutics’ ALPHA3 trial for cema-cel, an investigational CAR T therapy for large B-cell lymphoma. The study showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance, and their circulating tumor DNA levels dropped by a median of 97.7% compared to an increase in the observation arm. These findings suggest that cema-cel could prevent or delay clinical relapse in LBCL patients with molecular residual", "sentiment_score": 0.018516, "sentiment_label": "Neutral", "relevance_score": 0.314853, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "William Blair initiates Natera stock with Outperform on growth outlook", "url": "https://m.investing.com/news/analyst-ratings/william-blair-initiates-natera-stock-with-outperform-on-growth-outlook-93CH-4611328?ampMode=1", "date": "2026-04-13", "summary": "William Blair has initiated coverage on Natera Inc. (NASDAQ:NTRA) with an Outperform rating, citing the company's leading positions in diagnostic markets and its diversified, growing portfolio. Despite trading at a premium compared to peers, William Blair believes Natera's market leadership and first-mover advantage justify the valuation, expecting significant earnings power even though the company is not yet profitable. The article also mentions recent court decisions favoring Natera, board exp", "sentiment_score": 0.425419, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.582, "confidence": 0.58 } }, { "source": "alpha_vantage", "title": "Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma", "url": "https://www.businesswire.com/news/home/20260413928881/en/Natera-Highlights-Positive-Interim-Futility-Analysis-from-Allogene-Therapeutics-MRD-Guided-ALPHA3-Trial-in-Large-B-Cell-Lymphoma", "date": "2026-04-13", "summary": "Natera announced positive interim futility analysis from Allogene Therapeutics’ ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). The trial uses Natera's CLARITY™ MRD assay to identify high-risk patients. The analysis showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance, suggesting it may prevent or delay clinical relapse.", "sentiment_score": 0.425633, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "Court orders 30% ongoing royalty for Natera in patent dispute", "url": "https://www.msn.com/en-us/health/medical/court-orders-30-ongoing-royalty-for-natera-in-patent-dispute/ar-AA20vSFn", "date": "2026-04-12", "summary": "A court has ordered a 30% ongoing royalty payment to Natera stemming from a patent dispute. This decision implies a significant win for Natera regarding its intellectual property rights. The royalty structure suggests continued financial benefits for Natera from the disputed technology.", "sentiment_score": 0.801697, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera Claims Top Trading Volume as Legal Victory Sparks $550 Million Surge Amid Price Drop", "url": "https://www.bitget.com/amp/news/detail/12560605357844", "date": "2026-04-11", "summary": "Natera Inc. (NTRA) experienced a significant $550 million surge in trading volume despite a 4.91% price drop, following a favorable legal ruling that increased royalty rates from 10% to 30% on infringing MRD-related product sales. This legal victory strengthens Natera's intellectual property in the oncology diagnostics market but was met with profit-taking or reassessment by investors. The market is now keenly watching how these legal developments will translate into financial results in upcomin", "sentiment_score": 0.122652, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "alpha_vantage", "title": "NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA)", "url": "https://www.chartmill.com/stock/quote/NTRA/profile", "date": "2026-04-10", "summary": "This article provides a detailed overview of Natera Inc. (NTRA) stock, including its current price, performance metrics, and key statistics like market capitalization and EPS. It also covers technical and fundamental analysis ratings from ChartMill, recent earnings, future forecasts, and company profile information. Investors can find insights into the company's financial health, ownership structure, and comparisons with competitors in the biotechnology sector.", "sentiment_score": 0.103519, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera awarded 30% ongoing royalty in MRD patent litigation", "url": "https://www.msn.com/en-us/money/companies/natera-awarded-30-ongoing-royalty-in-mrd-patent-litigation/ar-AA20uqCc?uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-10", "summary": "Natera has been awarded a 30% ongoing royalty in its patent litigation concerning minimal residual disease (MRD) testing. This outcome follows an earlier court ruling that found certain of Natera's intellectual property was infringed. The royalty likely applies to future sales or activities related to the infringed patents.", "sentiment_score": 0.828768, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/court-win-on-mrd-patents-and-royalties-might-change-the-case", "date": "2026-04-10", "summary": "Natera recently secured a favorable court ruling, upholding the validity of its three MRD patents and granting a 30% royalty on infringing product sales. This decision bolsters Natera's intellectual property in molecular residual disease testing, potentially enhancing its market position and revenue outlook. While strengthening Natera's investment narrative, the article notes that investors should still consider risks such as high cash burn and challenges in clinical trials and reimbursement.", "sentiment_score": 0.412614, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-3-natera-inc-initial-statement-of-beneficial-ownership-d9ef1efdbc22.html", "date": "2026-04-10", "summary": "Natera, Inc. (NTRA) director Eric H. Rubin has filed an initial Form 3 with the SEC, formally establishing his status as an insider. This filing indicates that Rubin is a director of the company and brings him under insider reporting requirements, though it does not report any beneficial ownership of securities or trading activity. The Form 3 serves as an initial statement of beneficial ownership, providing transparency on his new insider role.", "sentiment_score": 0.019108, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle", "url": "https://www.benzinga.com/markets/equities/26/04/51727487/judge-hands-natera-30-ongoing-royalty-in-mrd-patent-battle", "date": "2026-04-09", "summary": "A Delaware court has awarded Natera a 30% ongoing royalty on post-injunction revenues related to its MRD patents, building on a previous 20.5% royalty for pre-injunction sales. The court also upheld the validity and infringement findings of Natera's patents against ArcherDx and Invitae, strengthening Natera's intellectual property portfolio. Natera's shares saw a slight increase in premarket trading following the announcement, and the company is expected to release its next financial update in M", "sentiment_score": 0.633715, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales", "url": "https://www.marketscreener.com/news/natera-says-court-orders-30-royalties-from-archerdx-invitae-on-post-injunction-sales-ce7e50dbd189f726", "date": "2026-04-09", "summary": "A court has ordered ArcherDx and Invitae to pay a 30% royalty to Natera for post-injunction sales. This decision follows a patent dispute and is expected to impact the financial performance of the involved diagnostic companies. Natera, a diagnostics company focusing on women's health, oncology, and organ health, will receive these royalties.", "sentiment_score": 0.441635, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "url": "https://in.investing.com/news/company-news/natera-wins-30-ongoing-royalty-in-patent-case-against-invitae-93CH-5329628", "date": "2026-04-09", "summary": "Natera Inc. has won a court decision granting it a 30% ongoing royalty on post-injunction revenues from certain minimal residual disease-related product sales by ArcherDx and Invitae. This ruling follows an earlier injunction and upholds the validity of Natera's MRD patents. The company, trading at $210.83 with a market capitalization of $29.88 billion, has seen its stock valuation positively influenced, with analysts revising earnings upwards despite an InvestingPro analysis suggesting it is cu", "sentiment_score": 0.481236, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-69aa6881ce05.html", "date": "2026-04-09", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NASDAQ: NTRA), exercised stock options to acquire 58,292 shares at $9.59 each and subsequently had 27,610 shares withheld at $204.87 for tax obligations. Following these transactions, Rabinowitz directly holds 2,383,162 shares and indirectly holds 5,000 shares through his spouse. The filing also details key figures like exercise price, tax-withholding price, and his holdings after the transactions.", "sentiment_score": 0.030797, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/NTRA/financials", "date": "2026-04-08", "summary": "This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.", "sentiment_score": 0.10698, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller", "url": "https://www.insidermonkey.com/blog/natera-inc-ntra-upside-potential-pulls-billionaire-stan-druckenmiller-1733871/?amp=1", "date": "2026-04-08", "summary": "Billionaire Stan Druckenmiller's Duquesne Capital holds a significant stake in Natera, Inc. (NTRA), increasing its position in the company which is recognized for its molecular residual disease test, Signatera. Natera's recent achievement of positive cash inflow in 2025 has shifted the narrative among institutional investors, mitigating concerns about cash burn and potential dilution risks. The article highlights the strong growth of Signatera and Natera's growing integration into clinical guide", "sentiment_score": 0.457358, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.businesswire.com/news/home/20260407837545/en/20-Abstracts-at-AACR-Highlight-Scale-Innovation-and-Clinical-Impact-of-Nateras-Oncology-Platform", "date": "2026-04-08", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 AACR Annual Meeting. These presentations highlight advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and the ongoing expansion of their molecular residual disease (MRD) and other capabilities. The research demonstrates Natera's innovative approaches to provide more precise and data-driven solutions in cancer care.", "sentiment_score": 0.484911, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300", "url": "https://www.moomoo.com/news/post/67968518/citi-maintains-natera-ntraus-with-buy-rating-maintains-target-price", "date": "2026-04-08", "summary": "Citi has reiterated its Buy rating for Natera (NTRA.US) and maintained a target price of $300. This continued endorsement suggests the firm sees strong potential for the company's performance, indicating a positive outlook on its valuation and business prospects.", "sentiment_score": 0.421377, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.biospace.com/press-releases/20-abstracts-at-aacr-highlight-scale-innovation-and-clinical-impact-of-nateras-oncology-platform", "date": "2026-04-07", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data from its oncology technologies will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. These presentations highlight the scale, innovation, and clinical impact of Natera's oncology platform, including advancements in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and expansion of molecular residual disease (MRD) capabilities. Key research areas inc", "sentiment_score": 0.406156, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating", "url": "https://www.gurufocus.com/news/8777278/natera-ntra-gets-90day-catalyst-watch-from-citi-and-maintains-buy-rating?mobile=true", "date": "2026-04-07", "summary": "Citi has placed Natera (NTRA) on a \"90-day catalyst watch\" and reaffirmed its Buy rating with a $300 price target, anticipating strong financial momentum despite a recent stock pullback. Natera, a diagnostic and research company, shows robust revenue growth and a strong balance sheet but faces challenges in profitability and has high institutional ownership alongside insider selling. The company's performance, particularly upcoming earnings, will be key to its future trajectory, requiring invest", "sentiment_score": 0.401433, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-56665-shares-in-natera-inc-ntra-purchased-by-robinhood-asset-management-llc-2026-04-07/", "date": "2026-04-07", "summary": "Robinhood Asset Management LLC recently acquired 56,665 shares of Natera, Inc. (NTRA) in the fourth quarter, a stake valued at approximately $12.98 million, making it their 23rd largest holding. While Natera exceeded Q4 earnings and revenue estimates, it remains unprofitable, and insiders have sold a significant number of shares recently. Despite high institutional ownership, analysts have a \"Moderate Buy\" consensus rating with an average target price of $253.47.", "sentiment_score": 0.169917, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Evercore Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $250", "url": "https://www.moomoo.com/news/post/67925664/evercore-maintains-natera-ntraus-with-buy-rating-cuts-target-price", "date": "2026-04-06", "summary": "Evercore has reiterated its Buy rating on Natera (NTRA.US) stock while simultaneously lowering its price target to $250. This adjustment indicates a continued positive outlook on the company despite potential short-term headwinds or revised growth expectations, reflected in the reduced target price. Investors will likely be watching Natera's performance closely in light of Evercore's maintained confidence but recalibrated valuation.", "sentiment_score": 0.046188, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of NTRA stock for approximately $606,899 on April 1, 2026. These sales, executed under a pre-arranged trading plan, occurred at prices ranging from $201.32 to $203.31 per share. This insider transaction comes as Natera stock trades above its InvestingPro Fair Value, suggesting potential overvaluation, though the company recently announced advancements in medical testing and an expanded board.", "sentiment_score": 0.051813, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-solomon-moshkevich-sells-3000-shares-of-stock-2026-04-03/", "date": "2026-04-04", "summary": "Natera insider Solomon Moshkevich recently sold 3,000 shares of the company's stock for over $600,000, reducing his stake by 1.99%. This transaction is part of a pattern of ongoing insider disposals by Moshkevich, who has made several other significant sales since January. Despite these insider sales, Natera recently exceeded quarterly EPS and revenue estimates and holds a \"Moderate Buy\" consensus analyst rating with a target price of $253.47.", "sentiment_score": -0.202477, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.992361, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490?ampMode=1", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of company stock for approximately $606,899 on April 1, 2026. These sales were executed under a pre-arranged trading plan, and Moshkevich still directly owns 147,882 shares. The article also touches on recent company developments, including new genetic tests and board expansion, and an adjusted price target by Morgan Stanley.", "sentiment_score": 0.121046, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock totaling $1.7 million on April 1, 2026. This insider sale followed a 55% surge in Natera's stock over the past year, placing it among InvestingPro's most overvalued companies. The company has recently launched new genomics tests and seen a price target adjustment from Morgan Stanley.", "sentiment_score": 0.058423, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-7cfdbe66df68.html", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of common stock on April 1, 2026, through an open-market transaction. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 26, 2024. Following these transactions, Moshkevich directly holds 147,882 shares of Natera.", "sentiment_score": -0.290353, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) legal chief sells 8,400 shares in preset 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-0e25ff27fe5c.html", "date": "2026-04-04", "summary": "Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold 8,400 shares of the company's common stock on April 1, 2026. The sales were conducted through a pre-arranged Rule 10b5-1 trading plan at weighted average prices between $200.47 and $205.50 per share. Following these transactions, Rabinowitz still holds 224,885 shares of Natera common stock.", "sentiment_score": 0.049691, "sentiment_label": "Neutral", "relevance_score": 0.322396, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491?ampMode=1", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock for $1.7 million on April 1, 2026, through a Rule 10b5-1 trading plan. This sale occurred as Natera's stock surged 55% over the past year. In other news, Natera launched Zenith genomics and its Signatera test showed promising results in cancer studies.", "sentiment_score": -0.202379, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair exercises 41,708 options, now holds 2.35M shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-2cb7102ee209.html", "date": "2026-04-02", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NTRA), exercised 41,708 stock options at a strike price of $9.59 per share. This transaction increased his direct holdings to 2,352,480 shares of Natera Common Stock, with an additional 58,292 stock options and 5,000 indirect shares through his spouse. The filing confirms no shares were sold and the options were fully exercisable.", "sentiment_score": 0.00667, "sentiment_label": "Neutral", "relevance_score": 0.300148, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Expands Board, Appoints Eric Rubin as Director", "url": "https://www.tipranks.com/news/company-announcements/natera-expands-board-appoints-eric-rubin-as-director", "date": "2026-04-01", "summary": "Natera has expanded its Board of Directors from ten to eleven members, appointing Eric Rubin as an independent Class I director effective March 26, 2026. Dr. Rubin will also join the Nominating, Corporate Governance and Compliance Committee and will receive standard director compensation. This move emphasizes Natera's commitment to independent oversight and regulatory compliance, with Dr. Rubin having no related-party ties to the company.", "sentiment_score": 0.255184, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Eric Rubin appointed to Natera board as Class I director", "url": "https://www.tradingview.com/news/tradingview:cf61fa6d2a1b1:0-eric-rubin-appointed-to-natera-board-as-class-i-director/", "date": "2026-04-01", "summary": "Natera has appointed Eric Rubin to its Board of Directors as a Class I director, effective March 26, 2026. This appointment increased the board's size from ten to eleven members, with Rubin also joining the Nominating, Corporate Governance and Compliance Committee. He will receive standard cash and equity compensation for non-employee directors, with his initial equity award vesting over three years.", "sentiment_score": 0.378267, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Eric Rubin joins Natera (NASDAQ: NTRA) board as independent director", "url": "https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-10e242e4f351.html", "date": "2026-04-01", "summary": "Natera, Inc. has expanded its Board of Directors to eleven members by appointing Eric Rubin as a Class I independent director, effective March 26, 2026. Dr. Rubin will serve on the Nominating, Corporate Governance and Compliance Committee and will receive standard cash and equity compensation, with his initial equity award vesting in three equal installments. An Indemnification Agreement has also been put in place for his service to the company.", "sentiment_score": 0.220476, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "J. Safra Sarasin Holding AG Makes New Investment in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-j-safra-sarasin-holding-ag-makes-new-investment-in-natera-inc-ntra-2026-04-01/", "date": "2026-04-01", "summary": "J. Safra Sarasin Holding AG recently acquired a new stake of 12,331 shares in Natera, Inc. (NASDAQ:NTRA), valued at approximately $2.83 million, during the fourth quarter. This move aligns with other institutional investors, contributing to Natera's 99.90% institutional ownership. Despite beating Q4 earnings estimates with $0.35 EPS and $665.5 million in revenue, the company remains unprofitable with significant insider selling recorded, while analysts hold a \"Moderate Buy\" consensus.", "sentiment_score": 0.187052, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/signatera-data-in-older-breast-cancer-patients-could-be-a-ga", "date": "2026-04-01", "summary": "Natera's Signatera molecular residual disease test has shown promising results in a new study, allowing older women with early-stage ER+/HER2- breast cancer to opt for primary endocrine therapy over surgery. This development could reshape Natera's investment narrative by reinforcing Signatera's clinical utility and potentially influencing future reimbursement decisions for various oncology indications. Despite optimistic forecasts, analysts remain cautious about the company's path to profitabili", "sentiment_score": 0.442638, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Allspring Global Investments Holdings LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-allspring-global-investments-holdings-llc-2026-04-01/", "date": "2026-04-01", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Natera, Inc. (NTRA) by 4.4% in the fourth quarter, selling 20,896 shares and retaining 454,498 shares. This comes amidst heavy insider selling, including transactions by CEO Steven Chapman and another insider, totaling over $74.1 million in the last quarter, though insiders still hold 5.63% of the stock. Despite this, institutional investors collectively own 99.90% of Natera's stock, and the company reported an EPS beat", "sentiment_score": 0.096429, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "url": "https://www.benzinga.com/news/health-care/26/03/51576065/nateras-signatera-data-suggests-select-breast-cancer-patients-could-skip-surgery", "date": "2026-03-31", "summary": "Natera's Signatera molecular residual disease (MRD) test has shown promising results, indicating that select breast cancer patients could potentially avoid surgery. A study published in Clinical Cancer Research demonstrated Signatera's ability to identify older women with early-stage ER+/HER2- breast cancer who can be effectively managed with primary endocrine therapy. The study highlights Signatera's strong predictive accuracy and early-detection capabilities, supporting its utility for non-sur", "sentiment_score": 0.034379, "sentiment_label": "Neutral", "relevance_score": 0.309954, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Avoiding Lag: Real-Time Signals in (NTRA) Movement", "url": "https://news.stocktradersdaily.com/news_release/12/Avoiding_Lag:_Real-Time_Signals_in_NTRA_Movement_033126033202_1774985522.html", "date": "2026-03-31", "summary": "This article provides a detailed analysis of Natera Inc. (NASDAQ: NTRA) movement, highlighting weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup, real-time signals, and multi-timeframe insights for traders.", "sentiment_score": 0.226243, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Zevenbergen Capital Investments LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-zevenbergen-capital-investments-llc-2026-03-31/", "date": "2026-03-31", "summary": "Zevenbergen Capital Investments LLC has reduced its stake in Natera, Inc. by 18% in the fourth quarter, selling 70,994 shares, although the stock still constitutes 1.6% of its portfolio. Despite this, other institutional investors have shown increased interest, while significant insider selling, including by the CFO and CEO, has occurred. Analysts maintain a \"Moderate Buy\" consensus for Natera, with an average price target of $253.47, following strong quarterly results that beat expectations.", "sentiment_score": 0.045284, "sentiment_label": "Neutral", "relevance_score": 0.305617, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "url": "https://www.stocktitan.net/news/NTRA/signatera-tm-mrd-identifies-breast-cancer-patients-who-can-forgo-ro16r8unwe94.html", "date": "2026-03-31", "summary": "A new study published in Clinical Cancer Research indicates that Natera's Signatera™ molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can safely forgo surgery and be managed with primary endocrine therapy. The study found that 100% of patients who were MRD-negative at baseline remained progression-free. These findings suggest that Signatera can help inform treatment decisions, potentially reducing the need for surgery in a vulnerable pat", "sentiment_score": 0.491134, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 6.88% on Mar 30", "url": "https://www.gurufocus.com/news/8756834/natera-inc-ntra-shares-down-688-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Natera Inc (NTRA) shares dropped 6.88% on March 30, closing at $182.65. Wall Street analysts project an average price target of $253.56, indicating a 38.82% upside, with an \"Outperform\" consensus recommendation. GuruFocus estimates a fair value of $213.11, suggesting a 16.68% upside from the current price.", "sentiment_score": -0.382935, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-dakota-wealth-management-buys-shares-of-5921-natera-inc-ntra-2026-03-29/", "date": "2026-03-29", "summary": "Dakota Wealth Management purchased 5,921 shares of Natera, Inc. (NASDAQ:NTRA), valued at approximately $1.36 million, in the fourth quarter, joining other institutional investors increasing their stake. Despite strong institutional ownership (99.90%), company insiders, including CEO Steven Leonard Chapman, have recently sold a significant number of shares. Natera exceeded Q4 earnings expectations with $0.35 EPS against an estimated -$0.46, and analysts maintain a \"Moderate Buy\" rating with an av", "sentiment_score": 0.270682, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "DAVENPORT & Co LLC Takes Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-davenport-co-llc-takes-position-in-natera-inc-ntra-2026-03-28/", "date": "2026-03-28", "summary": "DAVENPORT & Co LLC has initiated a new position in Natera, Inc. (NASDAQ: NTRA) during Q4, acquiring 14,032 shares valued at approximately $3.215 million. While institutional investors hold a significant portion of the stock, recent insider activity shows sales by CEO Steven Leonard Chapman and other insiders totaling over $74 million in the last 90 days. Natera recently beat quarterly earnings and revenue estimates and holds a \"Moderate Buy\" consensus rating from analysts with an average price t", "sentiment_score": 0.304125, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-assenagon-asset-management-sa-2026-03-28/", "date": "2026-03-28", "summary": "Assenagon Asset Management S.A. significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 85.5% in the fourth quarter, selling over 261,000 shares. Despite Natera reporting a surprise earnings beat with $0.35 EPS against a -$0.46 consensus, and revenue exceeding estimates, the company still has negative margins and analysts anticipate a negative EPS for the current year. Insider selling has also been observed, with major officers offloading shares, while institutional investors maintain a", "sentiment_score": -0.145015, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "A Look At Natera (NTRA) Valuation After Recent Share Price Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/a-look-at-natera-ntra-valuation-after-recent-share-price-wea", "date": "2026-03-28", "summary": "Natera (NTRA) has experienced recent share price weakness, though its long-term shareholder returns remain strong. Despite the pullback, the company is considered undervalued by some intrinsic estimates and analyst price targets, with a fair value pegged at $260.65 per share due to growth in molecular diagnostics. However, its current P/S ratio is above the industry average, suggesting less room for error if growth falters.", "sentiment_score": 0.340954, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 4.14% on Mar 27", "url": "https://www.gurufocus.com/news/8750024/natera-inc-ntra-shares-down-414-on-mar-27", "date": "2026-03-28", "summary": "Shares of Natera Inc (NTRA) dropped 4.14% on March 27, reaching an intraday low of $187.86 before settling at $188.02. This stock price is 26.66% below its 52-week high and 49.96% above its 52-week low. Wall Street analysts have an average target price of $253.56 for NTRA, indicating an \"Outperform\" status and a potential upside of 34.86%.", "sentiment_score": -0.208039, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:97d4478af094b:0-elanco-tandem-diabetes-fortrea-natera-and-myriad-genetics-shares-plummet-what-you-need-to-know/", "date": "2026-03-27", "summary": "Several stocks including Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics experienced significant drops in the afternoon trading session. This market downturn is attributed to rising uncertainty from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a dip in consumer confidence. Despite the broader market reaction, the article highlights potential buying opportunities in these quality stocks given that markets often overreact to news.", "sentiment_score": -0.228274, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.917985, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; reports 0 shares for Natera (NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/schedule-13g-a-natera-inc-amended-passive-investment-disclosure-b9cf16bd8fd9.html", "date": "2026-03-27", "summary": "Vanguard has reported 0 beneficial shares owned in Natera (NTRA) following an internal realignment effective January 12, 2026. This change means that certain Vanguard subsidiaries will now report their holdings separately, although their investment strategies remain unchanged. The filing indicates that The Vanguard Group itself no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.", "sentiment_score": 0.000143, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41981308", "title": "Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.", "authors": "Mahalingam D et al.", "journal": "Nature medicine", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41981308/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41980929", "title": "Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.", "authors": "Hansen DK et al.", "journal": "Blood cancer journal", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41980929/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41974150", "title": "Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.", "authors": "Colombo N et al.", "journal": "Lancet (London, England)", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41974150/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41974149", "title": "Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.", "authors": "Lorusso D et al.", "journal": "Lancet (London, England)", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41974149/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41972229", "title": "Donor-derived Cell-free DNA for Detection of Rejection After Pancreas Transplantation.", "authors": "Matar AJ et al.", "journal": "Transplantation direct", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41972229/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41968872", "title": "Absolute and Fractional Donor-Derived Cell-Free DNA in the Follow-Up of Kidney Allograft Rejection.", "authors": "Petr V et al.", "journal": "HLA", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41968872/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41963611", "title": "Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.", "authors": "Venturini J et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41963611/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41962310", "title": "New prognostic and predictive scoring systems for colorectal cancer liver metastases.", "authors": "Salvà F et al.", "journal": "ESMO open", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41962310/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41956543", "title": "HosTIL territory: mapping the landscape of toxicity in TIL therapy.", "authors": "Woodford R et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956543/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41955548", "title": "Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.", "authors": "Abidoye O et al.", "journal": "JCO precision oncology", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41955548/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41954938", "title": "Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.", "authors": "Leone JP et al.", "journal": "JAMA network open", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41954938/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41954928", "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "authors": "Gupta S et al.", "journal": "JAMA", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41953531", "title": "Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary.", "authors": "Sullivan MW et al.", "journal": "Gynecologic oncology reports", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41953531/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41953135", "title": "Concordance between genome-wide cfDNA screening and diagnostic test results for large copy-number variants: a multi-site study from the Global Expanded NIPT Consortium.", "authors": "Soster E et al.", "journal": "Frontiers in genetics", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41953135/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950572", "title": "From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.", "authors": "Ambrosini M et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Apr 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41950572/", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41945184", "title": "The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.", "authors": "Fadelu TA et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41945184/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41940628", "title": "SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.", "authors": "Peters S et al.", "journal": "Future oncology (London, England)", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41940628/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41939727", "title": "Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial.", "authors": "DeVore AD et al.", "journal": "Lancet regional health. Americas", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41939727/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41932032", "title": "Translating ctDNA into cutaneous melanoma care: An international expert survey.", "authors": "Geidel G et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41932032/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41931740", "title": "Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors.", "authors": "Bogdani C et al.", "journal": "JCO precision oncology", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41931740/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922555", "title": "A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.", "authors": "Fey T et al.", "journal": "Journal of cancer education : the official journal of the American Association for Cancer Education", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41922555/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41919756", "title": "How genetic counselors in North America describe their professional identity.", "authors": "Schwartz L et al.", "journal": "Journal of genetic counseling", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41919756/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41919242", "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "authors": "Szmyd C et al.", "journal": "Frontiers in oncology", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41919242/", "sentiment": { "label": "negative", "score": -0.848, "confidence": 0.85 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41912809", "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.", "authors": "Wainberg ZA et al.", "journal": "Nature medicine", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41908612", "title": "Three People With Recurrent Nephrolithiasis and Heterozygous ABCC6 Mutations.", "authors": "Farrell D et al.", "journal": "Kidney medicine", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41908612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41904847", "title": "Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).", "authors": "Knapp B et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41904847/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903855", "title": "Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (CMV D+R-) solid organ transplant recipients with prolonged follow-up: a ten-year experience.", "authors": "Heldman MR et al.", "journal": "American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903855/", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41903539", "title": "Advancing precision health discovery in a genetically diverse health system.", "authors": "Haas R et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41896510", "title": "ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.", "authors": "Gupta P et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895280", "title": "Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.", "authors": "Bandlamudi C et al.", "journal": "Cancer cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895280/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41891361", "title": "Disparities in Genetic Testing: Evaluation of Reproductive Carrier Screening in the United States.", "authors": "Parmar S et al.", "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41891361/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41890037", "title": "ATM functions as a rheostat of metabolic stress in small-cell lung cancer.", "authors": "Halder D et al.", "journal": "bioRxiv : the preprint server for biology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41890037/", "sentiment": { "label": "negative", "score": -0.802, "confidence": 0.8 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882705", "title": "Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.", "authors": "Swaminathan AC et al.", "journal": "Respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41875915", "title": "Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.", "authors": "Vargas CE", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41875915/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874669", "title": "Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.", "authors": "Chu DHT et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874669/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41873434", "title": "Advanced artificial intelligence vs simpler models for 1-year death prediction among patients receiving hemodialysis.", "authors": "K K et al.", "journal": "JAMIA open", "date": "2026-04-15", "url": "https://pubmed.ncbi.nlm.nih.gov/41873434/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41872254", "title": "Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.", "authors": "Nixon AB et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872254/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41864057", "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "authors": "Corti C et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864057/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41862950", "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "authors": "Holida M et al.", "journal": "Orphanet journal of rare diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862950/", "sentiment": { "label": "positive", "score": 0.753, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41862439", "title": "Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.", "authors": "Varga C et al.", "journal": "Blood cancer journal", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862439/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41860673", "title": "Photochemical transformation of paracetamol sensitized by humic acid: pH-dependent pathways and mechanisms.", "authors": "Barrera A et al.", "journal": "Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41860673/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }